Skip to content

Effect of Esketamine combined with Parecoxib sodium in Preemptive Analgesia on the quality of recovery and stress response in patients with laparoscopic surgery for gastric cancer: a randomized controlled trial

Effect of Esketamine combined with Parecoxib sodium on the quality of recovery in elderly patients with gastrointestinal malignant tumor radical surgery

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066169
Enrollment
Unknown
Registered
2022-11-25
Start date
2022-12-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastrointestinal malignant tumor radical surgery

Interventions

Group P:inject 40mg of Parecoxib sodium 15 minutes before anesthesia-induced.
Group E:Inject 0.25mg/kg Esketamine before anesthesia induction, 0.25mg/kg/h constant-speed infusion during the anesthesia maintenance period, and stop infusion 30 minutes before the end of the operat
Group PE:Inject Esketamine and Parecoxib sodium according to the methods of groups P and E respectively.

Sponsors

Department of Anesthesiology, Chaohu Hospital Affiliated to Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patients who intend to undergo laparoscopic gastrointestinal malignant tumor radical surgery under general anesthesia; 2. Age >= 60 years old; 3. ASAI - III, Mallampati grade I - II; 4. Receive patient-controlled intravenous analgesia (PCIA) treatment after surgery; 5. There are no serious lesions in important organs such as the heart, lungs and brain, and there are no obvious abnormalities in liver and kidney functions; 6. Sign the informed consent of the study.

Exclusion criteria

Exclusion criteria: 1. Allergic to the drugs needed in this study; 2. Patients with mental illness who are unable to cooperate; preoperative inability to communicate due to cognitive dysfunction or speech impairment; 3. Patients with abnormal heart, liver and kidney function; blood pressure >= 180/100 mmHg; untreated or poorly controlled hypertension; 4. Patients with glaucoma, increased intracranial pressure, hyperthyroidism/alcohodiagnos; 5. Other circumstances in which the researchers judge that the patient is not suitable to participate in the clinical trial.

Design outcomes

Primary

MeasureTime frame
Quality of postoperative recovery;Stress response:adrenaline and norepinephrine in plasma;

Secondary

MeasureTime frame
Stress response:adrenaline and norepinephrine in plasma;Total consumption propofol and remifentanil;time of postoperative revival and extubation;the exhaust time and the active time post-operation;

Countries

China

Contacts

Public ContactZhiguo Tao

Department of Anesthesiology, Chaohu Hospital Affiliated to Anhui Medical University

zhgtau@163.com+86 13625651122

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026